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ABSTRACT: Although cigarette smoking is a principal risk factor for bladder cancer in 
both men and women, few studies have statistically evaluated whether gender modifies the 
effect of smoking on bladder cancer risk. We initiated the present case-control study at 
Roswell Park Cancer Institute in Buffalo, New York, U.S., to provide further data on this 
important issue. We observed similar risk estimates for men and women with comparable 
smoking exposures, but did not observe a statistically significant interaction between gender 
and lifetime smoking exposure. We conclude that cigarette smoking is a major risk factor for 
bladder cancer in both sexes, but that gender does not modify the effect of smoking on blad-
der cancer risk. 
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Cigarette smoking is a major independent risk 
factor for urinary bladder cancer. Many epidemiologic 
studies conducted in various parts of the world have 
shown that both male and female cigarette smokers 
have two to four times the risk of developing bladder 
cancer compared to nonsmokers. In general, the risk 
increases as the frequency and duration of smoking 
levels increase, and risk typically decreases in former 
smokers compared to current smokers [1,2]. 
In a recent case-control study conducted in Los 
Angeles, California, U.S., Castelao and colleagues [3] 
reported that when men and women smoked compara-
ble amounts of cigarettes, women incurred a higher risk 
of bladder cancer than men. This conclusion was based 
in part from observing a statistically significant interac-
tion between sex and lifetime cigarette consumption in 
a regression model that predicted the risk of bladder 
cancer. This finding, if confirmed, would have implica-
tions for our understanding of the role of gender in the 
etiology of bladder cancer. In an effort to provide more 
data on this important issue, we conducted a hospital-
based case-control study to investigate the relationship 
between cigarette smoking and bladder cancer, and 
statistically evaluated whether gender was a potential 
effect modifier for the association between smoking 
and the risk of bladder cancer. 
 
SUBJECTS AND METHODS 
This study was approved by the Institutional Re-
view Board of Roswell Park Cancer Institute (RPCI) in 
Buffalo, New York, U.S., and informed consent was 
properly obtained from all participants. Study subjects 
included adult patients admitted to RPCI between 1982 
and 1998, who volunteered to complete a self-
administered epidemiologic questionnaire. The details 
of this hospital-based data collection system have been 
previously described [4]. Cases (n = 499; 381 males 
and 118 females) included patients diagnosed with pri-
mary, histologically confirmed bladder cancer. Over 
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fied as transitional cell carcinomas, which account for 
roughly 90% of bladder cancer presentations in the 
United States [5]. Cases were predominantly white 
(97%) and ranged in age from 24 to 90 years (mean age 
= 65.3 ± 10.7 years). Seventy-five percent (375/499) of 
cases were 60 years of age and older. Controls (n = 
1,922; 1,447 males and 475 females) included patients 
seen at RPCI who were discharged without a diagnosis 
of malignancy. Among a pool of 8,733 eligible patients, 
controls were frequency-matched to cases by sex and 
five-year age intervals for a final case-to-control ratio 
of approximately 1:4. Similar to cases, controls were 
predominantly white (99%) and ranged in age from 19 
to 94 years (mean age = 64.8 ± 10.9 years). The most 
frequently used clinical services for the male control 
patients included urology (23%), surgery (15%), and 
dermatology (12%), and the most common diagnoses 
included diseases of the digestive system (27%), dis-
eases of the circulatory system (24%), diseases of the 
breast and genito-urinary systems (11%), and diseases 
of the respiratory system (8%). The most frequently 
used clinical services for the female control patients 
included breast (22%), gynecology (17%), and surgery 
(14%), and the most common diagnoses included dis-
eases of the breast and genito-urinary systems (30%), 
diseases of the circulatory system (26%), and diseases 
of the digestive system (25%) . 
A patient was classified as an ever smoker, or 
never smoker, if he/she reported having smoked, or 
having not smoked, cigarettes every day for at least one 
year during his/her lifetime. Ever smokers were further 
classified as current or former smokers depending on 
whether the patient had reported quitting smoking at the 
time of questionnaire completion. Smoking histories 
were measured by the total number of years the patient 
reported smoking (duration), and the usual number of 
cigarettes smoked daily during years of regular use 
(frequency). A summary measure of lifetime smoking 
exposure (pack-years) was calculated as the product of 
frequency (packs/day) X duration (years).  
Unconditional multiple logistic regression was 
used to calculate odds ratio (OR) and 95% confidence 
interval (CI) estimates, and to test for the statistical 
significance of risk trends. OR and 95% CI estimates 
presented in this report are adjusted solely for age, 
which was entered as a continuous variable. Further 
adjustment for potential confounders such as occupa-
tional exposures (gasoline/oil, textiles, dyes, and chemi-
cals/acids/solvents), education, income, and geographic 
area of residence failed to notably alter point estimates. 
Gender was evaluated as a potential effect modifier for 
the association between smoking and the risk of bladder 
cancer by testing for the statistical significance of an 
interaction term (i.e., the product of pack-years of 
smoking and sex) in a logistic regression model [6]. All 
data analyses were performed using SPSS for Windows 
version 10.0 (SPSS Inc., Chicago, Illinois). Statistical 
tests were two-sided, and the level of significance was 
set at α = 0.05. 
 
RESULTS AND DISCUSSION 
Subject cigarette smoking histories and the results 
from the logistic regression analyses are presented in 
Table 1. Approximately 80% percent of cases and 63% 
of controls were classified as ever smokers. Among 
ever smokers, 31% of cases and 23% of controls were 
current smokers.  Compared to never smokers, ever 
smokers had a statistically significant two-fold in-
creased risk for bladder cancer in the total subject popu-
lation (OR = 2.4; 95% CI = 1.9 to 3.0), in males (OR = 
2.6; 95% CI = 1.9 to 3.5), and in females (OR = 2.1; 
95% CI = 1.4 to 3.2). Male current smokers (OR = 4.2; 
95% CI = 2.9 to 6.1) had a markedly increased risk for 
bladder cancer compared to female current smokers 
(OR = 2.1; 95% CI = 1.2 to 3.7). Compared to current 
smokers, former smokers had reduced risks of bladder 
cancer in the total subject population and in males, but 
not in females. 
 The risk of bladder cancer generally increased in 
both sexes as pack-years, duration, and frequency levels 
increased. We observed similar risk estimates for males 
and females with comparable smoking histories, and 
did not find a statistically significant interaction be-
tween lifetime smoking exposure and sex (P = 0.76), 
thereby leading us to conclude that gender was not an 
effect modifier for the association between smoking 
and bladder cancer in our case-control data. In the two 
other case-control studies that have formally tested for 
the statistical significance of an interaction term (i.e., 
the product of lifetime cigarette consumption and sex), 
Castelao and colleagues [3] detected a statistically sig-
nificant interaction (P = .016), while Burch and col-
leagues [7] did not (P = 0.13). 
The results of this study are consistent with those 
of other recent case-control studies from the United 
States [8,9,10] and Canada [7], which have reported 
approximately equivalent smoking-related risk esti-
mates for bladder cancer in males and females. Recent 
combined analyses of eleven case-control studies from 
Europe [11,12] also found that gender did not modify 
the association between smoking and bladder cancer,
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a 
  Total Subject Population Males Females 
  Cases Controls  OR 
(95% CI) 
b 
Cases Controls OR 
(95% CI) 
Cases Controls  OR 
(95% CI) 
Never smokers  100  718  1.0 (referent)  60  472  1.0 (referent)  40  246  1.0 (referent) 
Ever smokers  396  1198  2.4 (1.9-3.0)  318  970  2.6 (1.9-3.5)  78  228  2.1 (1.4-3.2) 
(Missing)  (3)  (6)    (3)  (5)     (1)  
Current smok-
ers 
122  271  3.4 (2.5-4.6)  95  190  4.2 (2.9-6.1)  27  81  2.1 (1.2-3.7) 
Former smok-
ers 
274  927  2.1 (1.6-2.7)  223  780  2.2 (1.6-3.0)  51  147  2.1 (1.3-3.4) 
Pack-years of smoking           
≤10  27  192  1.0 (0.64-1.6)  18  131  1.1 (0.62-1.9) 9 61  0.91  (0.42-2.0) 
11-20  44  182  1.7 (1.2-2.6)  32  145  1.7 (1.1-2.8)  12  37  2.0 (0.94-4.2) 
21-30  41  172  1.7 (1.2-2.6)  33  143  1.8 (1.1-2.9)  8  29  1.7 (0.72-4.0) 
31-40  52  166  2.3 (1.5-3.3)  40  136  2.3 (1.5-3.6)  12  30  2.5 (1.2-5.2) 
>40  218  436  3.6 (2.8-4.7)  185  374  3.9 (2.8-5.4)  33  62  3.3 (1.9-5.6) 
(Missing)  (14)  (50)    (10 (41)   (4)  (9)  
P for trend
c      <.001     <.001     .004 
Duration (years of smoking)           
1-10 19  134  1.0  (0.60-1.7)  14  103  1.1  (0.57-2.0) 5 31  0.98  (0.36-2.7) 
11-20  47  215  1.6 (1.1-2.3)  38  181  1.6 (1.1-2.6)  9  34  1.6 (0.70-3.6) 
21-30  69  250  2.0 (1.4-2.8)  52  200  2.0 (1.4-3.1)  17  50  2.1 (1.1-4.0) 
31-40  101  275  2.6 (1.9-3.6)  82  223  2.9 (2.0-4.2)  19  52  2.2 (1.2-4.2) 
>40  153  301  3.7 (2.8-4.9)  127  244  4.1 (2.9-5.8)  26  57  2.8 (1.6-5.0) 
(Missing)  (7)  (23)   (5)  (19)   (2)  (4)   
P for trend      <.001      <.001      .022 
Frequency (cigarettes per day)            
1-10  45  230  1.4 (0.96-2.1)  30  149  1.6 (0.99-2.6)  15  81  1.1 (0.60 - 2.2) 
11-20  168  506  2.4 (1.8-3.1)  131  415  2.5 (1.8-3.4)  37  91  2.5 (1.5 - 4.2) 
21-30  51  170  2.2 (1.5-3.2)  42  141  2.4 (1.5-3.7)  9  29  1.9 (0.84 - 4.4) 
31-40  90  187  3.5 (2.5-4.9)  80  168  3.8 (2.6-5.6)  10  19  3.3 (1.4 - 7.6) 
>40  33  79  3.0 (1.9-4.8)  29  74  3.1 (1.9-5.2)  4  5  4.9 (1.3 - 19.2) 
(Missing)  (9)  (26)   (6)  (23)   (3)  (3)   
P  for  trend      <.001     <.001     .005 
aAdjusted for age 
bOR = odds ratio, CI = confidence interval 
cP = probability 
 with males and females sharing nearly identical risks 
regardless of duration or frequency levels. 
It is important to consider that in most popula-
tions worldwide, bladder cancer is relatively rare in 
women. Men have approximately three to four times 
the risk of developing bladder cancer compared to 
women, and this sex difference in risk persists even 
after controlling for differences in smoking and occupa-
tional exposures [1,2,5,9]. The exact causes for the ob-
served excess risk of bladder cancer in men are cur-
rently not known. Future research should continue to 
explore possible explanations for this excess risk, in-
cluding potential sex differences in genetic, anatomic, 
and hormonal factors, urination habits, and perhaps 
previously unidentified environmental risk factors 
[1,9,13]. In summary, in this case-control investigation 
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factor for bladder cancer in both sexes, and that for 
comparable cigarette smoking exposures, men and 
women shared similar risk estimates for bladder cancer. 
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